FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to a novel compound of formula
(I)
or its pharmaceutically acceptable salt, possessing properties of the IKKβ and TNFα inhibitor. The compound can be used with an additional therapeutic agent, selected from vincristine, camptothecin hydrochloride (CPT-11), lefunomid, dexamethasone and TNFα. Preferable are compounds of formula (I), corresponding to 2-{5-chloro-2-[(1R,2R)-2-hydroxycyclopentylamino]pyrimidin-4-yl}-N-cyclopropyl-1H-indole-4-carboxamide and 2-{5-chloro-2-[(1R,2S)-2-hydroxycyclopentylamino]pyrimidin-4-yl}-N-cyclopropyl-1H-indole-4-carboxamide.
EFFECT: compound can be applied in the treatment of inflammatory diseases such as rheumatoid arthritis, chronic obstructive lung disease, bronchial asthma, multiple sclerosis and intestinal inflammatory diseases, or cancer diseases, such as multiple myeloma, colon cancer, pancreas cancer and ovary cancer, by IKKβ inhibition.
30 cl, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VESICLES OBTAINED FROM LACTOBACILLUS PARACASEI AND THEIR USE | 2019 |
|
RU2785709C2 |
| USE OF ARSENIC COMPOUNDS TO TREAT TISSUE OR ORGAN REJECTION | 2013 |
|
RU2665362C2 |
| USE OF ARSENIC COMPOUNDS FOR PAIN MANAGEMENT AND INFLAMMATION TREATMENT | 2008 |
|
RU2630574C2 |
| USE OF ARSENIC COMPOUNDS FOR PAIN MANAGEMENT AND INFLAMMATION TREATMENT | 2008 |
|
RU2468806C2 |
| 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE-METHYL, POLYMORPHOUS FORMS AND METHODS FOR USE THEREOF | 2014 |
|
RU2693833C2 |
| ASK1-INHIBITING PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | 2018 |
|
RU2772422C2 |
| KINASE INHIBITORS | 2007 |
|
RU2440352C2 |
| FUCOSIDASE INHIBITORS | 2016 |
|
RU2765202C2 |
| PHARMACEUTICAL COMPOSITION BASED ON TRIINDOLYLMETHANE DERIVATIVE AS ANTI-TUMOUR MEDICATION | 2012 |
|
RU2549430C2 |
| THERAPEUTIC COMBINATIONS CONTAINING INHIBITOR OF POLY(ADP-RIBOSE)POLYMERASE | 2005 |
|
RU2361592C2 |
